Neurology Clinical Trials

Statistical methods in neurology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All neurology trials

31 results

• AIM-HIGHIndependent statistical analysis of AIM-HIGH, the randomized phase 3 trial of extended-release niacin plus simvastatin versus placebo plus simvastatin for prevention of vascular events, including its time-to-event endpoints, Cox model, hazard ratios,…Phase 3Results postedn = 3,414NCT00120289
• ALIASIndependent statistical analysis of ALIAS, a randomized phase 3 trial of albumin versus saline in acute ischemic stroke, including trial design, endpoints, logistic regression, risk ratios, nonparametric analysis, safety, and interpretation.Phase 3Results postedn = 841NCT00235495
• ATLANTICIndependent statistical analysis of ATLANTIC (NCT01347580), a randomized phase 4 trial comparing pre-hospital versus in-hospital initiation of ticagrelor in STEMI patients planned for PCI.Phase 4Results postedn = 1,875NCT01347580
• CARE-MS IIndependent statistical analysis of CARE-MS I, a randomized phase 3 trial comparing alemtuzumab with interferon beta-1a in relapsing-remitting multiple sclerosis, including endpoint definitions, hazard ratios, rate ratios, longitudinal analyses, and statistical interpretation.Phase 3Results postedn = 581NCT00530348
• CARE-MS IIComplete statistical analysis of CARE-MS II, a randomized phase 3 trial comparing alemtuzumab with interferon beta-1a in relapsing-remitting multiple sclerosis, including primary endpoints, statistical methods, secondary analyses, safety, and interpretation.Phase 3Results postedn = 840NCT00548405
• CIRTComplete statistical analysis of CIRT (NCT01594333), a randomized phase 3 trial of methotrexate versus placebo in cardiovascular disease, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank testing, stratification, multiplicity, safety, and statistical…Phase 3Results postedn = 4,786NCT01594333
• CLARITYIndependent statistical analysis of the phase 3 CLARITY trial of oral cladribine in relapsing-remitting multiple sclerosis, including randomized design, annualized qualifying relapse rate, relative risks, confidence intervals, chi-squared testing, intention-to-treat analysis, and…Phase 3Results postedn = 1,326NCT00213135
• COMPASSIndependent statistical analysis of the COMPASS phase 3 trial of rivaroxaban-based antithrombotic treatment in coronary or peripheral artery disease, including trial design, time-to-event endpoints, hazard ratios, safety outcomes, statistical methods, and interpretation.Phase 3Results postedn = 27,395NCT01776424
• COSSIndependent statistical analysis of the COSS phase 3 trial of extracranial-intracranial bypass surgery versus best medical therapy for symptomatic carotid occlusion, including its primary endpoint, secondary analyses, statistical methods, and interpretation.Phase 3Results postedn = 700NCT00029146
• CRESTIndependent statistical analysis of CREST (NCT00004732), a randomized double-masked trial comparing carotid endarterectomy with carotid artery stenting for patients with carotid stenosis.Phase NAResults postedn = 2,502NCT00004732
• CRYSTAL-AFIndependent statistical analysis of CRYSTAL-AF, evaluating continuous cardiac monitoring with an insertable cardiac monitor for atrial fibrillation detection after cryptogenic stroke or transient ischemic attack.Phase 4Results postedn = 447NCT00924638
• ENGAGEIndependent statistical analysis of the ENGAGE phase 3 trial of aducanumab in early Alzheimer's disease, including randomized trial design, CDR-SB and cognitive endpoints, MMRM methodology, confidence intervals, p-values, and safety.Phase 3Results postedn = 1,653NCT02477800
• ENGAGE AF-TIMI 48Independent statistical analysis of ENGAGE AF-TIMI 48, evaluating edoxaban versus warfarin for stroke and systemic embolic events in patients with atrial fibrillation.Phase 3Results postedn = 21,105NCT00781391
• EVOLVE-1Independent statistical analysis of the phase 3 EVOLVE-1 trial of galcanezumab for the prevention of episodic migraine, including randomized design, longitudinal mixed-effects analysis, odds ratios, Fisher exact testing, efficacy results, safety, and…Phase 3Results postedn = 862NCT02614183
• EVOLVE-2Independent statistical analysis of the phase 3 EVOLVE-2 trial of galcanezumab for the prevention of episodic migraine, including trial design, registered endpoints, mixed-effects analyses, confidence intervals, secondary outcomes, safety information, and statistical…Phase 3Results postedn = 986NCT02614196
• EXPEDITION 3Independent statistical analysis of EXPEDITION 3 (NCT01900665), a randomized phase 3 trial comparing solanezumab with placebo in participants with mild Alzheimer's disease, including the registered ADAS-Cog14 endpoint, mixed-effects analysis, confidence interval, p-value,…Phase 3Results postedn = 2,129NCT01900665
• NAVIGATE ESUSIndependent statistical analysis of NAVIGATE ESUS, a randomized phase 3 trial comparing rivaroxaban with aspirin in patients with recent embolic stroke of undetermined source, including time-to-event methods, primary and secondary results, safety,…Phase 3Results postedn = 7,213NCT02313909
• POINTComplete statistical analysis of the POINT phase 3 trial of clopidogrel versus placebo in transient ischemic attack, including trial design, 90-day efficacy and hemorrhage endpoints, hazard ratios, confidence intervals, log-rank testing, and…Phase 3Results postedn = 4,881NCT00991029
• PRISMSIndependent statistical analysis of the PRISMS phase 3 trial of alteplase in participants with mild stroke, covering the Day 90 modified Rankin Scale endpoint, risk difference, odds ratios, safety outcomes, trial design,…Phase 3Results postedn = 313NCT02072226
• PRoFESSAn independent statistical analysis of PRoFESS (NCT00153062), including its randomized double-blind design, recurrent-stroke endpoints, Cox proportional-hazards analyses, non-inferiority framework, hazard ratios, confidence intervals, and secondary outcomes.Phase 4Results postedn = 20,332NCT00153062
• PROMISE-2Independent statistical analysis of the PROMISE-2 phase 3 trial of ALD403 (eptinezumab) for the prevention of chronic migraine, including trial design, endpoints, ANCOVA, MMRM, Cochran-Mantel-Haenszel analyses, reported results, safety, and statistical interpretation.Phase 3Results postedn = 1,121NCT02974153
• RE-LYComplete statistical analysis of the RE-LY phase 3 trial of dabigatran versus warfarin, including randomized trial design, time-to-event endpoints, Cox proportional-hazards analyses, non-inferiority and superiority comparisons, safety, and statistical interpretation.Phase 3Results postedn = 18,113NCT00262600
• RE-SPECT ESUSIndependent statistical analysis of RE-SPECT ESUS, the randomized phase 3 trial of dabigatran etexilate versus aspirin for secondary stroke prevention after embolic stroke of undetermined source. Includes trial design, time-to-event endpoints, Cox…Phase 3Results postedn = 5,390NCT02239120
• ROCKET AFIndependent statistical analysis of ROCKET AF, the randomized phase 3 trial of rivaroxaban versus warfarin for prevention of stroke and non-CNS systemic embolism in patients with non-valvular atrial fibrillation.Phase 3Results postedn = 14,269NCT00403767
• SOCRATESIndependent statistical analysis of the SOCRATES phase 3 trial of ticagrelor versus acetylsalicylic acid after acute ischaemic stroke or transient ischaemic attack, including endpoint definitions, Cox and logistic regression methods, efficacy results,…Phase 3Results postedn = 13,307NCT01994720
• STRIVEComplete statistical analysis of the STRIVE phase 3 trial of erenumab for migraine prevention, including randomized trial design, primary and secondary endpoint analyses, mixed-effects models, Cochran-Mantel-Haenszel testing, multiplicity, and safety.Phase 3Results postedn = 955NCT02456740
• STROKE-AFIndependent statistical analysis of STROKE-AF (NCT02700945), a randomized trial evaluating atrial fibrillation detection through 12 months with Reveal LINQ insertable cardiac monitoring after recent ischemic stroke of presumed known origin.Phase NAResults postedn = 496NCT02700945
• SURMOUNT-OSAIndependent statistical analysis of SURMOUNT-OSA, a randomized phase 3 trial of tirzepatide in participants with obstructive sleep apnea and obesity, including AHI results, ANCOVA, logistic regression, confidence intervals, and safety.Phase 3Results postedn = 469NCT05412004
• THALESComplete statistical analysis of the phase 3 THALES trial of ticagrelor versus placebo in acute ischaemic stroke and transient ischaemic attack, including trial design, endpoints, Cox and logistic regression methods, efficacy results,…Phase 3Results postedn = 11,016NCT03354429
• TRA 2P-TIMI 50Independent statistical analysis of TRA 2P-TIMI 50 (NCT00526474), including randomized trial design, time-to-event endpoints, Cox proportional-hazards methods, efficacy results, bleeding outcomes, post-hoc analyses, and statistical interpretation.Phase 3Results postedn = 26,449NCT00526474
• TRAILBLAZER-ALZ 2A detailed statistical analysis of TRAILBLAZER-ALZ 2, a randomized phase 3 study of donanemab versus placebo in participants with early Alzheimer's disease, including endpoint results, mixed-effects models, ANCOVA, confidence intervals, and interpretation.Phase 3Results postedn = 1,736NCT04437511

← All therapeutic areas